Rheumatoid Arthritis Drugs Market by Drug Class (Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others), Route of Administration (Oral and Parenteral), and Sales Channel (Prescription-based Drugs, and Over-the-counter Drugs): Global Opportunity Analysis and Industry Forecast, 2027
The Rheumatoid Arthritis (RA) drugs market refers to the pharmaceuticals and biologic therapies developed for the treatment of rheumatoid arthritis, an autoimmune disease characterized by chronic inflammation of the joints. The goal of RA treatment is to manage symptoms, slow down the progression of the disease, and improve the quality of life for patients. The global healthcare expenditure has been steadily increasing, driven by factors such as population growth, aging demographics, and the prevalence of chronic diseases like RA. Governments and healthcare organizations are investing more in healthcare infrastructure and treatment options, including RA drugs. This increased healthcare spending contributes to the growth of the Rheumatoid Arthritis drugs market. The market is majorly restricted by the alternative treatment options. Rheumatoid Arthritis Drugs Market is likely to grow at a rate of 3.0% CAGR by 2027.
Rheumatoid Arthritis Drugs Market based on Drug Class Type
BS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed-presentation IBS (IBS-M)
Rheumatoid Arthritis Drugs Market based on Route Of Administration
Rifaximin
Eluxadoline
Lubiprostone
Linaclotide
Rheumatoid Arthritis Drugs Market based on Sales Channel
Prescription-based Drugs
Over-the-counter Drugs
Rheumatoid Arthritis Drugs Market based on Geography
North America
Europe
Asia Pacific
Rest of the World
The market for rheumatoid arthritis drugs is driven by the increasing prevalence of the disease globally and the growing demand for effective treatment options. Various types of medications are used in the management of RA, including:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs are commonly used to relieve pain and reduce inflammation in RA. These drugs help alleviate symptoms but do not slow down the progression of the disease.
Disease-Modifying Antirheumatic Drugs (DMARDs): DMARDs are a class of medications that work to slow down the progression of RA by targeting the underlying autoimmune response. Conventional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, are often prescribed as first-line treatments. They help reduce inflammation, relieve symptoms, and protect joint structures.
Biologic Response Modifiers: Biologic DMARDs, also known as biologics, are a newer class of drugs that target specific molecules in the immune system involved in the inflammatory response of RA. Biologics, such as tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors, and Janus kinase (JAK) inhibitors, have revolutionized the treatment of RA and have shown significant efficacy in reducing symptoms, preventing joint damage, and improving long-term outcomes.
Corticosteroids: Corticosteroids are potent anti-inflammatory medications that can provide rapid relief of RA symptoms. They are often used for short-term management during disease flares or as a bridge therapy while waiting for other medications to take effect. Long-term use of corticosteroids is generally avoided due to their potential side effects.
The rheumatoid arthritis drugs market is highly competitive, with several pharmaceutical companies involved in research, development, and marketing of these medications. Advances in biotechnology and the emergence of biosimilars (lower-cost versions of biologic drugs) have increased treatment options and affordability.
The major leading companies of the rheumatoid arthritis drugs market are Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis Ag (Sandoz), Pfizer Inc., Ucb S.A.
In addition to pharmaceuticals, the market also includes healthcare providers, rheumatologists, and other healthcare professionals who diagnose and manage RA. Physical therapists and occupational therapists also play essential roles in improving patients' physical function and quality of life.
As research continues and our understanding of the underlying mechanisms of rheumatoid arthritis expands, new therapeutic targets and innovative drugs are expected to enter the market. Personalized medicine approaches, such as precision therapies based on genetic and biomarker profiles, may also shape the future of RA treatment.
It's worth observing that market trends and dynamics can change over time. For the most up-to-date information on the current state of the cephalosporin market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the rheumatoid arthritis drugs market in the forecast period.
An exact estimation of the rheumatoid arthritis drugs market share and its contribution to the parent market is provided in the report.
Further profiles of major competitors and their dynamic strategies are also included in the report.
Rheumatoid Arthritis Drugs Market based on Drug Class Type
BS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed-presentation IBS (IBS-M)
Rheumatoid Arthritis Drugs Market based on Route Of Administration
Rifaximin
Eluxadoline
Lubiprostone
Linaclotide
Rheumatoid Arthritis Drugs Market based on Sales Channel
Prescription-based Drugs
Over-the-counter Drugs
Rheumatoid Arthritis Drugs Market based on Geography
North America
Europe
Asia Pacific
Rest of the World
The market for rheumatoid arthritis drugs is driven by the increasing prevalence of the disease globally and the growing demand for effective treatment options. Various types of medications are used in the management of RA, including:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs are commonly used to relieve pain and reduce inflammation in RA. These drugs help alleviate symptoms but do not slow down the progression of the disease.
Disease-Modifying Antirheumatic Drugs (DMARDs): DMARDs are a class of medications that work to slow down the progression of RA by targeting the underlying autoimmune response. Conventional DMARDs, such as methotrexate, sulfasalazine, and leflunomide, are often prescribed as first-line treatments. They help reduce inflammation, relieve symptoms, and protect joint structures.
Biologic Response Modifiers: Biologic DMARDs, also known as biologics, are a newer class of drugs that target specific molecules in the immune system involved in the inflammatory response of RA. Biologics, such as tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors, and Janus kinase (JAK) inhibitors, have revolutionized the treatment of RA and have shown significant efficacy in reducing symptoms, preventing joint damage, and improving long-term outcomes.
Corticosteroids: Corticosteroids are potent anti-inflammatory medications that can provide rapid relief of RA symptoms. They are often used for short-term management during disease flares or as a bridge therapy while waiting for other medications to take effect. Long-term use of corticosteroids is generally avoided due to their potential side effects.
The rheumatoid arthritis drugs market is highly competitive, with several pharmaceutical companies involved in research, development, and marketing of these medications. Advances in biotechnology and the emergence of biosimilars (lower-cost versions of biologic drugs) have increased treatment options and affordability.
The major leading companies of the rheumatoid arthritis drugs market are Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis Ag (Sandoz), Pfizer Inc., Ucb S.A.
In addition to pharmaceuticals, the market also includes healthcare providers, rheumatologists, and other healthcare professionals who diagnose and manage RA. Physical therapists and occupational therapists also play essential roles in improving patients' physical function and quality of life.
As research continues and our understanding of the underlying mechanisms of rheumatoid arthritis expands, new therapeutic targets and innovative drugs are expected to enter the market. Personalized medicine approaches, such as precision therapies based on genetic and biomarker profiles, may also shape the future of RA treatment.
It's worth observing that market trends and dynamics can change over time. For the most up-to-date information on the current state of the cephalosporin market, it is advisable to refer to recent market research reports, industry publications, and engage with experts in the pharmaceutical sector. An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.
Detailed information about the attributes which are generating growth in the rheumatoid arthritis drugs market in the forecast period.
An exact estimation of the rheumatoid arthritis drugs market share and its contribution to the parent market is provided in the report.
Further profiles of major competitors and their dynamic strategies are also included in the report.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG CLASS TYPE: MARKET SIZE & ANALYSIS
5.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
5.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Uric Acid Drugs
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Oral
6.2. Parenteral
7. SALES CHANNEL: MARKET SIZE & ANALYSIS
7.1. Prescription-based Drugs
7.2. Over-the-counter Drugs
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. ELI LILLY AND COMPANY.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. JOHNSON & JOHNSON
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. F. HOFFMANN-LA ROCHE LTD
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. NOVARTIS AG (SANDOZ).
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. AMGEN INC
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. UCB S.A.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. BRISTOL-MYERS SQUIBB COMPANY.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. PFIZER INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. MERCK & CO., INC
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. ABBVIE INC
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG CLASS TYPE: MARKET SIZE & ANALYSIS
5.1. Disease-modifying Anti-rheumatic Drugs (DMARDs)
5.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Uric Acid Drugs
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Oral
6.2. Parenteral
7. SALES CHANNEL: MARKET SIZE & ANALYSIS
7.1. Prescription-based Drugs
7.2. Over-the-counter Drugs
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. ELI LILLY AND COMPANY.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. JOHNSON & JOHNSON
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. F. HOFFMANN-LA ROCHE LTD
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. NOVARTIS AG (SANDOZ).
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. AMGEN INC
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. UCB S.A.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. BRISTOL-MYERS SQUIBB COMPANY.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. PFIZER INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. MERCK & CO., INC
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. ABBVIE INC
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR CORTICOSTEROIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR URIC ACID DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR PRESCRIPTION-BASED DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR OVER-THE-COUNTER DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. U.SRHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 17. U.SRHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 18. U.SRHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. CANADARHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 20. CANADARHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 21. CANADARHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 22. EUROPERHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPERHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 24. EUROPERHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 25. EUROPERHEUMATOID ARTHRITIS DRUGS MARKETVALUE, SALES CHANNEL,2021-2027 (USD BILLION)
TABLE 26. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 27. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. U.K RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 30. U.K RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 31. U.K RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE2021-2027 (USD BILLION)
TABLE 33. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 34. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 35. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 36. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 37. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 39. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 40. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 41. ROE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 42. ROE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 43. ROE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 48. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 49. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 50. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 51. INDIA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 52. INDIA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 53. INDIA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 54. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 55. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 56. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 63. ELI LILLY AND COMPANY: FINANCIALS
TABLE 64. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 65. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 66. JOHNSON & JOHNSON.: FINANCIALS
TABLE 67. JOHNSON & JOHNSON: PRODUCTS & SERVICES
TABLE 68. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 69. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 70. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 71. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 72. NOVARTIS AG (SANDOZ): FINANCIALS
TABLE 73. NOVARTIS AG (SANDOZ): PRODUCTS & SERVICES
TABLE 74. NOVARTIS AG (SANDOZ): RECENT DEVELOPMENTS
TABLE 75. AMGEN INC: FINANCIALS
TABLE 76. AMGEN INC: PRODUCTS & SERVICES
TABLE 77. AMGEN INC: RECENT DEVELOPMENTS
TABLE 78. UCB S.A.: FINANCIALS
TABLE 79. UCB S.A: PRODUCTS & SERVICES
TABLE 80. UCB S.A: RECENT DEVELOPMENTS
TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 84. PFIZER INC: FINANCIALS
TABLE 85. PFIZER INC: PRODUCTS & SERVICES
TABLE 86. PFIZER INC: RECENT DEVELOPMENTS
TABLE 87. MERCK & CO., INC: FINANCIALS
TABLE 88. MERCK & CO., INC: PRODUCTS & SERVICES
TABLE 89. MERCK & CO., INC: RECENT DEVELOPMENTS
TABLE 90. ABBVIE INC: FINANCIALS
TABLE 91. ABBVIE INC: PRODUCTS & SERVICES
TABLE 92. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR CORTICOSTEROIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR URIC ACID DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR PRESCRIPTION-BASED DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DRUGS MARKET VALUE FOR OVER-THE-COUNTER DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. U.SRHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 17. U.SRHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 18. U.SRHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. CANADARHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 20. CANADARHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 21. CANADARHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 22. EUROPERHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPERHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 24. EUROPERHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 25. EUROPERHEUMATOID ARTHRITIS DRUGS MARKETVALUE, SALES CHANNEL,2021-2027 (USD BILLION)
TABLE 26. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 27. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 28. GERMANY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. U.K RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 30. U.K RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 31. U.K RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE2021-2027 (USD BILLION)
TABLE 33. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 34. FRANCE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 35. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 36. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 37. ITALY RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 39. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 40. SPAIN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 41. ROE RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 42. ROE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 43. ROE RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 48. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 49. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 50. CHINA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 51. INDIA RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 52. INDIA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 53. INDIA RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 54. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKET VALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 55. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 56. JAPAN RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY DRUG CLASS TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD RHEUMATOID ARTHRITIS DRUGS MARKETVALUE, BY SALES CHANNEL, 2021-2027 (USD BILLION)
TABLE 63. ELI LILLY AND COMPANY: FINANCIALS
TABLE 64. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 65. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 66. JOHNSON & JOHNSON.: FINANCIALS
TABLE 67. JOHNSON & JOHNSON: PRODUCTS & SERVICES
TABLE 68. JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 69. F. HOFFMANN-LA ROCHE LTD: FINANCIALS
TABLE 70. F. HOFFMANN-LA ROCHE LTD: PRODUCTS & SERVICES
TABLE 71. F. HOFFMANN-LA ROCHE LTD: RECENT DEVELOPMENTS
TABLE 72. NOVARTIS AG (SANDOZ): FINANCIALS
TABLE 73. NOVARTIS AG (SANDOZ): PRODUCTS & SERVICES
TABLE 74. NOVARTIS AG (SANDOZ): RECENT DEVELOPMENTS
TABLE 75. AMGEN INC: FINANCIALS
TABLE 76. AMGEN INC: PRODUCTS & SERVICES
TABLE 77. AMGEN INC: RECENT DEVELOPMENTS
TABLE 78. UCB S.A.: FINANCIALS
TABLE 79. UCB S.A: PRODUCTS & SERVICES
TABLE 80. UCB S.A: RECENT DEVELOPMENTS
TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 84. PFIZER INC: FINANCIALS
TABLE 85. PFIZER INC: PRODUCTS & SERVICES
TABLE 86. PFIZER INC: RECENT DEVELOPMENTS
TABLE 87. MERCK & CO., INC: FINANCIALS
TABLE 88. MERCK & CO., INC: PRODUCTS & SERVICES
TABLE 89. MERCK & CO., INC: RECENT DEVELOPMENTS
TABLE 90. ABBVIE INC: FINANCIALS
TABLE 91. ABBVIE INC: PRODUCTS & SERVICES
TABLE 92. ABBVIE INC: RECENT DEVELOPMENTS
